XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   10,012      
Beginning balance at Dec. 31, 2022 $ 181,518 $ 1 $ 985,660 $ (1,531) $ (802,612)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 4,563   4,563    
Common stock issued upon release of restricted stock units (in shares)   45      
Restricted stock surrendered for taxes 0        
Foreign currency translation adjustments (7)     (7)  
Unrealized gain (loss) on marketable securities, net 739     739  
Net loss (29,056)       (29,056)
Ending balance (in shares) at Mar. 31, 2023   10,057      
Ending balance at Mar. 31, 2023 157,757 $ 1 990,223 (799) (831,668)
Beginning balance (in shares) at Dec. 31, 2022   10,012      
Beginning balance at Dec. 31, 2022 181,518 $ 1 985,660 (1,531) (802,612)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Foreign currency translation adjustments (12)        
Unrealized gain (loss) on marketable securities, net 937        
Net loss (60,566)        
Ending balance (in shares) at Jun. 30, 2023   10,099      
Ending balance at Jun. 30, 2023 131,155 $ 1 994,938 (606) (863,178)
Beginning balance (in shares) at Mar. 31, 2023   10,057      
Beginning balance at Mar. 31, 2023 157,757 $ 1 990,223 (799) (831,668)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 4,469   4,469    
Common stock issued under employee stock purchase plan (in shares)   42      
Common stock issued under employee stock purchase plan 246   246    
Foreign currency translation adjustments (5)     (5)  
Unrealized gain (loss) on marketable securities, net 198     198  
Net loss (31,510)       (31,510)
Ending balance (in shares) at Jun. 30, 2023   10,099      
Ending balance at Jun. 30, 2023 131,155 $ 1 994,938 (606) (863,178)
Beginning balance (in shares) at Dec. 31, 2023   10,143      
Beginning balance at Dec. 31, 2023 83,469 $ 1 1,003,718 (473) (919,777)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 4,166   4,166    
Issuance of common stock and pre-funded warrants for cash in private placement, net of issuance costs of $8,449 (in shares)   10,573      
Issuance of common stock and pre-funded warrants for cash in private placements, net of issuance costs of $8,449 119,361 $ 1 119,360    
Common stock issued upon exercise of stock options (in shares)   14      
Common stock issued upon exercise of stock options 139   139    
Common stock issued upon release of restricted stock units (in shares)   25      
Foreign currency translation adjustments (19)     (19)  
Unrealized gain (loss) on marketable securities, net (41)     (41)  
Net loss (24,787)       (24,787)
Ending balance (in shares) at Mar. 31, 2024   20,755      
Ending balance at Mar. 31, 2024 182,288 $ 2 1,127,383 (533) (944,564)
Beginning balance (in shares) at Dec. 31, 2023   10,143      
Beginning balance at Dec. 31, 2023 $ 83,469 $ 1 1,003,718 (473) (919,777)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued upon exercise of stock options (in shares) 14        
Foreign currency translation adjustments $ (9)        
Unrealized gain (loss) on marketable securities, net (43)        
Net loss (43,263)        
Ending balance (in shares) at Jun. 30, 2024   20,801      
Ending balance at Jun. 30, 2024 168,029 $ 2 1,131,592 (525) (963,040)
Beginning balance (in shares) at Mar. 31, 2024   20,755      
Beginning balance at Mar. 31, 2024 182,288 $ 2 1,127,383 (533) (944,564)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 3,945   3,945    
Common stock issued upon release of restricted stock units (in shares)   2      
Common stock issued under employee stock purchase plan (in shares)   44      
Common stock issued under employee stock purchase plan 264   264    
Foreign currency translation adjustments 10     10  
Unrealized gain (loss) on marketable securities, net (2)     (2)  
Net loss (18,476)       (18,476)
Ending balance (in shares) at Jun. 30, 2024   20,801      
Ending balance at Jun. 30, 2024 $ 168,029 $ 2 $ 1,131,592 $ (525) $ (963,040)